Pyramid Biosciences, Inc.

Industry

  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
See more in Biomedtracker

Latest on Pyramid Biosciences, Inc.

Scrip

Deal Watch: Japan’s SNBL To Re-Absorb US Spinout Satsuma

 
• By Joseph Haas, Lisa Takagi, and Dexter Jie Yan

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. SNBL To Pay 28% Premium To Re-Acquire S

Scrip

Deal Watch: Sanofi To Tap Owkin’s AI, Machine Learning In Oncology

 
• By Joseph Haas and Jung Won Shin

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Sanofi Hopes Owkin Can Aid Oncology Dis

Scrip

Finance Watch: CF Foundation Commits $110m In Partnership With Flagship’s Pioneering Medicines

 
• By Mandy Jackson

The biotechnology company creator and funder Flagship Pioneering and the Cystic Fibrosis Foundation announced a strategic partnership on 3 November under which the CF Foundation has committed up to

Scrip

Finance Watch: One Small Pain Drug Maker And Three Biotech SPACs Launch IPOs

 
• By Mandy Jackson

The summer of 2020 has been a busy one for US biopharmaceutical company initial public offerings, but after 14 in June and 12 in July there were just six in August – although that’s still the third mo